Beijing Tan

Discovery of (<i>S</i>)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1<i>H</i>-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus

Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, John Litchfield et al. · Journal of Medicinal Chemistry · 2011 · 115 citations · Full text

Life Sciences, Biochemistry, Pharmacology +14

A Novel Relay Method for Determining Low-Clearance Values

Li Di, Patrick Trapa, R. Scott Obach et al. · Drug Metabolism and Disposition · 2012 · 109 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Accelerant classification by gas chromatography/mass spectrometry and multivariate pattern recognition

Beijing Tan, James K. Hardy, Ralph E Snavely · Analytica Chimica Acta · 2000 · 88 citations

Pharmacy, Chemistry, Pharmaceutical Analysis +11

Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus

Amit S. Kalgutkar, Meera Tugnait, Tong Zhu et al. · Drug Metabolism and Disposition · 2011 · 71 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, Peter J. Oates et al. · MedChemComm · 2011 · 68 citations

Pharmacy, Biochemistry, Medicinal Chemistry +12